Scholar Rock Holding (SRRK) Common Equity (2017 - 2026)
Scholar Rock Holding's quarterly Common Equity came in at $276.0 million in Q1 2026, down 11.63% year-on-year from $312.3 million in Q1 2025, and up 12.43% quarter-over-quarter from $245.5 million in Q4 2025.
Scholar Rock Holding has reported Common Equity for 10 years, with the latest figure at $276.0 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity fell 11.63% year-over-year to $276.0 million; the trailing twelve-month figure through Mar 2026 stood at $276.0 million (down 11.63% YoY), and the FY2025 full-year result was $245.5 million, down 33.41% from the prior year.
- Common Equity for Q1 2026 stood at $276.0 million, up from $245.5 million in the prior quarter.
- The five-year high for Common Equity was $368.6 million in Q4 2024, with the low at $79.2 million in Q3 2024.
- Average Common Equity over 5 years is $232.6 million, with a median of $233.3 million recorded in 2025.
- Year-over-year, Common Equity slumped 52.77% in 2024 and surged 209.35% in 2025.
- Tracing SRRK's Common Equity over 5 years: stood at $260.2 million in 2022, then declined by 13.46% to $225.2 million in 2023, then soared by 63.68% to $368.6 million in 2024, then tumbled by 33.41% to $245.5 million in 2025, then gained by 12.43% to $276.0 million in 2026.
- The last three Common Equity figures came in at $276.0 million (Q1 2026), $245.5 million (Q4 2025), and $245.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 276.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 276.01 Mn |
| Dec 31, 2025 | 245.49 Mn |
| Sep 30, 2025 | 245.00 Mn |
| Jun 30, 2025 | 233.29 Mn |
| Mar 31, 2025 | 312.33 Mn |
| Dec 31, 2024 | 368.63 Mn |
| Sep 30, 2024 | 79.20 Mn |
| Jun 30, 2024 | 133.62 Mn |
| Mar 31, 2024 | 182.77 Mn |
| Dec 31, 2023 | 225.22 Mn |
| Sep 30, 2023 | 167.67 Mn |
| Jun 30, 2023 | 202.50 Mn |
| Mar 31, 2023 | 228.65 Mn |
| Dec 31, 2022 | 260.24 Mn |
| Sep 30, 2022 | 293.27 Mn |
| Jun 30, 2022 | 329.51 Mn |
| Mar 31, 2022 | 171.32 Mn |
| Dec 31, 2021 | 172.07 Mn |
| Sep 30, 2021 | 187.26 Mn |
| Jun 30, 2021 | 216.66 Mn |
| Mar 31, 2021 | 240.54 Mn |
| Dec 31, 2020 | 260.77 Mn |
| Sep 30, 2020 | 62.98 Mn |
| Jun 30, 2020 | 82.17 Mn |
| Mar 31, 2020 | 98.65 Mn |
| Dec 31, 2019 | 112.90 Mn |
| Sep 30, 2019 | 121.79 Mn |
| Jun 30, 2019 | 128.96 Mn |
| Mar 31, 2019 | 97.52 Mn |
| Dec 31, 2018 | 106.62 Mn |
| Sep 30, 2018 | 102.34 Mn |
| Jun 30, 2018 | 111.61 Mn |
| Mar 31, 2018 | -61.93 Mn |
| Dec 31, 2017 | -53.52 Mn |